Epigenetic modifications of prostate-derived Ets transcription factor in breast cancer cells

  • Authors:
    • Yamini Sabherwal
    • Nitin Mahajan
    • Ming Zhang
  • View Affiliations

  • Published online on: August 6, 2013     https://doi.org/10.3892/or.2013.2661
  • Pages: 1985-1988
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The importance of epigenetic alterations such as DNA methylation, histone modification and nucleosome remodeling in breast cancer is well established. Epigenetic alterations are reversible, and much research has been focused on understanding these alterations with the aim of developing effective therapies. Prostate-derived Ets factor (PDEF) is a member of the Ets family of transcription factors and has long been under investigation for its key role in tumor development and progression. To date, no studies have been conducted to elucidate the epigenetic modifications of PDEF in cancer progression. Using breast and prostate cancer cells, we investigated the effect of the methylation inhibitor 5' azacytidine (AZA) on the expression of PDEF in these cells. The inhibition of methylation observed was specific to breast cancer cells as experiments with prostate cells did not exhibit any significant change. Notably, the expression of p21, a cyclin-dependent kinase (CDK) inhibitor 1 and also a target gene of PDEF, was found to be positively correlated with PDEF expression following 5'AZA treatment. Inhibition of methylation led to a decrease in the proliferation rate of MDA-MB-468 cells as revealed by MTT proliferation assay. Other epigenetic alterations such as histone modifications were not observed in these breast cancer cells following treatment with specific HDAC inhibitors. Our data suggest the possibility of epigenetic modification of PDEF due to DNA methylation and involvement of the cell cycle inhibitor p21. Future studies on the epigenetic alterations of PDEF in correlation with p21 or other targets may facilitate the development of effective therapies for the treatment of breast cancer.
View Figures
View References

Related Articles

Journal Cover

October 2013
Volume 30 Issue 4

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Sabherwal Y, Mahajan N and Zhang M: Epigenetic modifications of prostate-derived Ets transcription factor in breast cancer cells. Oncol Rep 30: 1985-1988, 2013.
APA
Sabherwal, Y., Mahajan, N., & Zhang, M. (2013). Epigenetic modifications of prostate-derived Ets transcription factor in breast cancer cells. Oncology Reports, 30, 1985-1988. https://doi.org/10.3892/or.2013.2661
MLA
Sabherwal, Y., Mahajan, N., Zhang, M."Epigenetic modifications of prostate-derived Ets transcription factor in breast cancer cells". Oncology Reports 30.4 (2013): 1985-1988.
Chicago
Sabherwal, Y., Mahajan, N., Zhang, M."Epigenetic modifications of prostate-derived Ets transcription factor in breast cancer cells". Oncology Reports 30, no. 4 (2013): 1985-1988. https://doi.org/10.3892/or.2013.2661